Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Faldaprevir SGC vs Solution in Healthy Volunteers
NCT02182284Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2008
- Primary completion
- Feb 2008
- Modality
- Small Molecules, Modified Peptides
01
Overview
Phase 1, randomised, open-label trial of faldaprevir in hepatitis C (HCV) (2 cohorts), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve from 0 to infinity and Maximum plasma concentration. Started Jan 2008; status: completed.
02
Drugs
faldaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02182284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182284.